Drug intelligence / Profile preview

CARDIX-101

Development stage: Phase 2
Lead developer: Cardix Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

CARDIX-101 is an investigational oral drug under development by Cardix Therapeutics for the treatment of chronic bradycardia, a condition characterized by abnormally slow heart rate. The drug aims to improve cardiac function by increasing heart rate and cardiac output, potentially providing a pharmacological alternative to pacemaker implantation for patients with bradycardia. As of 2025, there are no regulatory-approved drugs specifically indicated for this use in the United States or globally. Clinical studies are ongoing to evaluate its safety and efficacy in this indication[1][2][3][4].

Other names: CARDIX-101ACARDIX101ACARDIX 101A

Beyond the preview

Go deeper on CARDIX-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CARDIX-101.

Explore the full profile